Compare ADMA Biologics Inc (ADMA) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Direxion Daily S&P 500 Bull 3X Shares trades at $267.87. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SPXL | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $288.04 |
52-Week Low | $7.60 | $170.20 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SPXL, a leveraged ETF tracking the S&P 500, trades at $275.77, up 2.62% with strong bullish technical signals from moving averages. Recent sector rotation has pressured tech stocks, though broader market optimism persists. The fund's performance is tied to daily S&P 500 returns, with a dividend scheduled for June 2026.
Outlook remains tied to S&P 500 momentum, with potential for gains if earnings meet high expectations, but risks include volatility decay from daily rebalancing and market corrections. Investors should weigh the ETF's leverage against broader economic indicators and sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
